JOHNSON DAVID LEE

Global Blood Therapeutics, Inc. [ GBT ]

1. Name and Address of Reporting Person

C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO CA 94080

2. Issuer Name and Ticker or Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)

10/01/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

Other (specify below)
Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

JOHN DAVID LEE

1. Title of Security (Instr. 3)

2. Title of Derivative Security (Instr. 3)

3. Conversion or Exercise Price of Derivative Security

4. Transacted at or Greater than:

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

8. Price of Derivative Security (Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Common Stock

Common Stock

10/01/2020

10/01/2020

M

4,375

A

24,890

D

F

2,170

D

57.96

22,720

D

10/01/2020

4,375

(1)

Common Stock

$0.00

13,125

D

(1)

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

2. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs.

3. The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

/\ Tricia Suvari, as Attorney-in-Fact

* Intentional misstatements or omissions of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 8 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Signature of Reporting Person

Date

10/05/2020

Washington, D.C. 20549

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

INCORPORATED